TransMedics Group, Inc. (NASDAQ:TMDX) Shares Sold by Pitcairn Co.

Pitcairn Co. lessened its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 34.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,993 shares of the company’s stock after selling 2,063 shares during the period. Pitcairn Co.’s holdings in TransMedics Group were worth $627,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TMDX. Vaughan Nelson Investment Management L.P. purchased a new stake in TransMedics Group in the 2nd quarter worth approximately $39,862,000. Driehaus Capital Management LLC boosted its holdings in TransMedics Group by 15.8% during the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after buying an additional 202,867 shares in the last quarter. Principal Financial Group Inc. grew its position in TransMedics Group by 260.1% during the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after buying an additional 146,115 shares during the period. Hood River Capital Management LLC purchased a new position in TransMedics Group in the second quarter valued at $18,854,000. Finally, Canada Pension Plan Investment Board purchased a new position in TransMedics Group in the second quarter valued at $16,086,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TMDX. Oppenheimer lowered their target price on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. Robert W. Baird cut their price objective on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, October 29th. Stephens upped their target price on TransMedics Group from $151.00 to $178.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. TD Cowen dropped their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Finally, Piper Sandler reduced their price objective on shares of TransMedics Group from $180.00 to $110.00 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $131.80.

TransMedics Group Trading Up 3.3 %

Shares of TMDX opened at $78.58 on Tuesday. TransMedics Group, Inc. has a 52-week low of $67.77 and a 52-week high of $177.37. The stock has a market cap of $2.64 billion, a PE ratio of 83.60 and a beta of 2.08. The firm’s fifty day moving average is $117.72 and its two-hundred day moving average is $137.49. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The business had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s revenue was up 63.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.12) earnings per share. Research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the transaction, the chief executive officer now owns 61,643 shares in the company, valued at $9,457,269.06. The trade was a 12.27 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the completion of the sale, the insider now directly owns 20,843 shares of the company’s stock, valued at $3,089,766.32. This represents a 12.43 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,958 shares of company stock worth $3,470,328 over the last ninety days. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.